



Press Kit

SONA NANOTECH INC.

Company Information

Tickers	CSE: SONA OTCQB: SNANF
Website	https://www.sonanano.com/
Corporate Address	1969 Upper Water Street Suite 2001, Halifax, Nova Scotia B3J 3R7, Canada
Linkedin	https://www.linkedin.com/company/sona-nanotech-inc/
Twitter	https://twitter.com/sonananotech
YouTube	https://www.youtube.com/channel/UCCK3VsReQEBrSY_gi5jWtFA
Instagram	https://www.instagram.com/sona_nanotech/
Mentions (Twitter)	@SonaNanotech
Mentions LinkedIn	@sona-nanotech-inc @david-regan-3a665b4 – David Regan, CEO

Company Details

Company Email	info@sonanano.com
Contact Number	1-902-442-0653
Presentations	https://www.sonanano.com/investor-presentations/
Let's Connect	https://www.sonanano.com/contact/
Latest Press Releases	https://www.sonanano.com/category/news-releases/

About Sona Nanotech

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) is a nanotechnology company in pre-clinical development of Targeted Hyperthermia Therapy (THT), a photothermal therapy to eliminate tumors gently, from the inside out. By leveraging the power of nanotechnology, Sona Nanotech is working towards revolutionizing the approach to cancer therapies and diagnostics. With a commitment to innovation and research, the company is dedicated to improving patient outcomes.

Sona Nanotech's Targeted Hyperthermia Therapy uses nanoparticles and IR light to selectively destroy cancerous cells while minimizing damage to healthy tissues. This approach holds the potential to provide effective and targeted treatment options for patients, ultimately leading to improvement in both treatment outcomes and quality of life.

Sona Nanotech is actively conducting a study to assess the efficacy of Targeted Hyperthermia Therapy in treating colorectal cancer alongside the Giacomantonio Immuno-Oncology Research Group. Sona Nanotech envisions a future where these advancements contribute to tangible improvements in patient outcomes.


To learn more: <https://www.sonanano.com/>.

Our Story

At Sona, our story is one of innovation, perseverance, and a deep-rooted commitment to improving lives through cutting-edge medical technology. Our journey has been fueled by a passionate team of scientists who strive to push the boundaries of what's possible. With unwavering dedication, we are developing groundbreaking therapies and diagnostic solutions that harness the power of nanotechnology to transform patient outcomes. We invite you to delve into our inspiring story and witness the transformative impact we are aiming to make in the world of cancer treatment.


Discover more about our journey at: <https://www.sonanano.com/our-story/>

Board of Directors & Leadership

<u>Image</u>	<u>Title</u>	<u>Name</u>
	Chair	Mark Lievonen

BIO


Mark Lievonen is an accomplished professional and a prominent figure in the biotechnology industry. He brings a wealth of expertise to his role as the Chair of Sona Nanotech, as the past president of Sanofi Pasteur Limited, a leading global vaccine manufacturer. His contribution to the field is further exemplified by his role as the Co-Chair of the Government of Canada's COVID-19 Vaccine Task Force, where he plays a pivotal role in guiding the country's vaccination strategy. In addition to his involvement with Sona Nanotech, Lievonen serves as a director for Quest PharmaTech, Biome Grow, and the Gairdner Foundation. With an MBA and as a Fellow of the Chartered Professional Accountants of Ontario (FCPA), Lievonen possesses strong business acumen and financial expertise, with his track record and portfolio of experience providing tremendous value to Sona Nanotech.

<u>Image</u>	<u>Title</u>	<u>Name</u>
	Director	Walter Strapps

BIO


Walter Strapps is renowned in the field of biotechnology for his contributions to the development of antivirals and RNA therapeutics. As a Director of Sona Nanotech, Strapps brings a wealth of expertise and experience to the board. From his role as the CSO of Liberate Bio, a pioneering company focused on discovering lipid nanoparticle delivery vehicles, backed by Khosla Ventures. Prior to his role at Liberate Bio, Strapps held positions including CEO at Carver Bioscience and Chief Scientific Officer at Gemini Therapeutics. Strapps holds an M.A., M.Phil., and Ph.D. from Columbia University, underscoring his deep understanding of scientific research

and development. His expertise in RNA therapeutics, coupled with his entrepreneurial spirit, make him an asset to Sona Nanotech.

Image	Title	Name
	Director	Neil Fraser


BIO

As a Director at Sona Nanotech, Neil Fraser brings a wealth of experience in the healthcare and medical device sectors. As the past president of Medtronic Canada for 20 years, a leading medical technology company. Fraser contributed to the advancement of the Canadian healthcare landscape as a member of the Life Sciences Strategy Council for the Canadian Chamber of Commerce where he helped shape policies and strategies prior to his retirement. His involvement in Health Canada's Advisory Panel on Health Innovation further underscores his commitment to fostering innovation in healthcare. He is also a director at Cloud DX, a digital healthcare company. Fraser holds a B.A.Sc. and an MBA, combining technical knowledge with business acumen to make strategic contributions.

Image	Title	Name
	Director	James Megann


BIO

James Megann is an experienced finance professional with a diverse background in venture capital, capital markets, and marketing bringing over 25 years of experience. Currently serving as the Managing Director of Numus Financial, he has completed over \$1.5 billion in transactions. Megann also serves on the board of Torrent Capital. With his knowledge of the communications and marketing industry, James brings perspective to Sona Nanotech's strategic initiatives. Notably, his community work has earned him recognition, including the Queens Diamond Jubilee medal in 2012.

Image	Title	Name
	Director & CSO	Len Pagliaro, PhD

BIO

Len Pagliaro began his career as a Professor of Bioengineering and Laboratory Medicine at the University of Washington. With 24 years of experience in biotechnology products, services, and technology licensing, he has a deep understanding of the industry's intricacies. Len's track record includes his role as a key contributor to the commercialization efforts at BioImage, where he led the concept to a \$26 million profit and loss (P&L) in just four years. This success ultimately led to the acquisition and integration of BioImage by ThermoFisher Scientific. As the CEO of Dynamic Light, Inc., he demonstrated his leadership skills by spearheading the spinout of an academic team and achieving first revenues in under three years.

Image	Title	Name
	CEO	David Regan

BIO

David Regan brings to his role as CEO significant experience as a strategy consultant and corporate director. With 15 years of experience in public companies, he has a deep understanding of strategy, investor relations, and corporate development. David graduated with an MBA from INSEAD and a BBA (Hons) from St. Francis Xavier University.

Technology Overview


For a comprehensive understanding of Sona Nanotech's technologies, explore our Technology Overview page at <https://www.sonanano.com/technology-overview/>. This resource provides detailed insights into the innovative approaches we employ to drive potential advancements in the field of medical science. One notable aspect is the utilization of hyperthermia thermal therapy for cancer treatment, a concept that is discussed in the document "The Case for Hyperthermia Thermal Therapy for Cancer" available at <http://www.sonanano.com/wp-content/uploads/2023/06/The-Case-for-Hyperthermia-Thermal-Therapy-for-Cancer-Sona-Nanotech.pdf>. This informative document presents the scientific rationale and evidence supporting the efficacy of hyperthermia therapy in the context of cancer treatment. It discusses the principles behind Targeted Hyperthermia Therapy (THT) and its ability to selectively target and destroy cancer cells while sparing healthy tissues. Sona Nanotech's therapies offer a promising alternative or complementary approach to traditional cancer treatments. The Technology Overview page details our proprietary gold nanorods and their versatile applications in imaging and targeted drug delivery.

Therapies

Sona Nanotech has been committed to pushing the boundaries of medical science through technology. Through our Targeted Hyperthermia Therapy (THT), we aim to revolutionize cancer

treatment by using specially designed nanoparticles to selectively destroy cancer cells while minimizing harm to healthy tissue. Additionally, our proprietary gold nanorods provide a versatile platform for a variety of potential applications, including imaging and targeted drug delivery. To learn more about our technology and their applications, visit our website at <https://www.sonanano.com/technology-overview/>. Explore our page on Targeted Hyperthermia Therapy (THT) to understand the transformative potential of this approach in cancer treatment: <https://www.sonanano.com/therapies/tht/>. Dive into our pre-clinical study section to gain insights into the research and development process behind our therapies: <https://www.sonanano.com/therapies/pre-clinical-study/>.

Partnerships and Associations

The National Cancer Institute's Nanotechnology Characterization Laboratory (NCL)
 The logo for the National Cancer Institute's Nanotechnology Characterization Laboratory (NCL). It features a circular graphic on the left composed of a central grey circle surrounded by a ring of green dots of varying sizes, resembling a sunburst or a molecular structure. To the right of this graphic, the letters "NCL" are written in a large, bold, green, sans-serif font. Below "NCL", the words "Nanotechnology", "Characterization", and "Laboratory" are stacked vertically in a smaller, grey, sans-serif font.
The National Cancer Institute's Nanotechnology Characterization Laboratory (NCL) has been instrumental in assisting Sona Nanotech in their assessment of Sona's GNR technology. By collaborating with the NCL, Sona Nanotech has gained access to critical resources and assessments. This assistance from the NCL helps Sona Nanotech validate the characteristics of its critical GNR materials. The collaboration with the NCL reinforces Sona Nanotech's commitment to rigorous scientific evaluation and helps to ensure that their technology meets the highest standards of safety.
1. https://www.sonanano.com/sona-nanotech-receives-technology-assessment-results-from-ncl/
2. https://www.sonanano.com/positive-results-of-second-assessment-of-sona-gnr-technology/
3. https://www.sonanano.com/new-ncl-assessment-of-sona-gnr-technology-improvement-success/

Minnetronix Medical



Sona Nanotech entered a supplier relationship with Minnetronix Medical, a Minneapolis-based medical device design and manufacturing company. This collaboration marks a significant milestone for Sona Nanotech, as it selected Minnetronix to engineer the next generation of Targeted Hyperthermia Therapy light devices.

By teaming up with Minnetronix, Sona Nanotech gained access to their extensive expertise in medical device engineering and manufacturing. Minnetronix's record of accomplishment in developing innovative medical technologies and their commitment to quality make them an ideal partner for Sona Nanotech. With this collaboration, Sona Nanotech can leverage Minnetronix's resources and capabilities to accelerate the development and commercialization of their Targeted Hyperthermia Therapy light device.

1. <https://www.sonanano.com/sona-selects-minnetronix-to-engineer-next-generation-targeted-hyperthermia-cancer-therapy-light-device/>